Genedx Holdings Corp Stock Performance
| WGS Stock | 76.35 1.65 2.12% |
On a scale of 0 to 100, GeneDx Holdings holds a performance score of 3. The company retains a Market Volatility (i.e., Beta) of 1.31, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, GeneDx Holdings will likely underperform. Please check GeneDx Holdings' potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether GeneDx Holdings' current trending patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in GeneDx Holdings Corp are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak technical and fundamental indicators, GeneDx Holdings unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.12) | Five Day Return 16.12 | Year To Date Return (4.12) | Ten Year Return (76.39) | All Time Return (76.39) |
Last Split Factor 1:33 | Last Split Date 2023-05-04 |
1 | Insider Sell Kevin Feeley Sells 22,000 Shares of GeneDx Holdings Corp | 11/26/2024 |
2 | Disposition of 718 shares by Kevin Feeley of GeneDx Holdings subject to Rule 16b-3 | 11/29/2024 |
3 | Disposition of 263 shares by Kevin Feeley of GeneDx Holdings at 78.3912 subject to Rule 16b-3 | 12/02/2024 |
4 | Disposition of 337 shares by Kevin Feeley of GeneDx Holdings at 77.0427 subject to Rule 16b-3 | 01/02/2025 |
5 | Disposition of 10005 shares by Katherine Stueland of GeneDx Holdings at 96.3877 subject to Rule 16b-3 | 01/07/2025 |
6 | Acquisition by Bryan Dechairo of 37497 shares of GeneDx Holdings subject to Rule 16b-3 | 01/14/2025 |
7 | GeneDx Holdings Corp Shares Up 3.21 percent on Jan 24 | 01/24/2025 |
8 | GeneDx Holdings Corp Announces Upcoming Financial Results Release for Q4 and Full Year 2024 | 01/28/2025 |
9 | GeneDx Stock Price Down 5.6 percent - Heres What Happened - MarketBeat | 01/30/2025 |
10 | Dubai to Gather More Than 30 Heads of State and Government, Global Leaders at the World Governments Summit 2025 | 02/03/2025 |
11 | GeneDx Holdings Corp Shares Down 7.66 percent on Feb 6 | 02/06/2025 |
12 | GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment | 02/10/2025 |
13 | Schwab, Georgieva Discuss New Era of Global Transformations at World Governments Summit in Dubai | 02/12/2025 |
14 | GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patien... | 02/13/2025 |
| Begin Period Cash Flow | 137.4 M | |
| Free Cash Flow | -185.9 M |
GeneDx |
GeneDx Holdings Relative Risk vs. Return Landscape
If you would invest 7,104 in GeneDx Holdings Corp on November 19, 2024 and sell it today you would earn a total of 531.00 from holding GeneDx Holdings Corp or generate 7.47% return on investment over 90 days. GeneDx Holdings Corp is generating 0.249% of daily returns assuming volatility of 5.1716% on return distribution over 90 days investment horizon. In other words, 46% of stocks are less volatile than GeneDx, and above 96% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
GeneDx Holdings Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GeneDx Holdings' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GeneDx Holdings Corp, and traders can use it to determine the average amount a GeneDx Holdings' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0481
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | WGS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.17 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.25 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average GeneDx Holdings is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GeneDx Holdings by adding it to a well-diversified portfolio.
GeneDx Holdings Fundamentals Growth
GeneDx Stock prices reflect investors' perceptions of the future prospects and financial health of GeneDx Holdings, and GeneDx Holdings fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GeneDx Stock performance.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.0827 | ||||
| Profit Margin | (0.31) % | ||||
| Operating Margin | (0.10) % | ||||
| Current Valuation | 2.1 B | ||||
| Shares Outstanding | 27.47 M | ||||
| Price To Book | 10.26 X | ||||
| Price To Sales | 7.85 X | ||||
| Revenue | 202.57 M | ||||
| Gross Profit | 162.63 M | ||||
| EBITDA | (136.46 M) | ||||
| Net Income | (175.77 M) | ||||
| Total Debt | 119.77 M | ||||
| Book Value Per Share | 7.45 X | ||||
| Cash Flow From Operations | (180.15 M) | ||||
| Earnings Per Share | (3.09) X | ||||
| Market Capitalization | 2.1 B | ||||
| Total Asset | 473.67 M | ||||
| Retained Earnings | (1.3 B) | ||||
| Working Capital | 123.52 M | ||||
About GeneDx Holdings Performance
Assessing GeneDx Holdings' fundamental ratios provides investors with valuable insights into GeneDx Holdings' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the GeneDx Holdings is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 25.95 | 40.43 | |
| Return On Tangible Assets | (0.67) | (0.70) | |
| Return On Capital Employed | (0.36) | (0.37) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (0.89) | (0.93) |
Things to note about GeneDx Holdings Corp performance evaluation
Checking the ongoing alerts about GeneDx Holdings for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GeneDx Holdings Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GeneDx Holdings Corp had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 202.57 M. Reported Net Loss for the year was (175.77 M) with profit before taxes, overhead, and interest of 162.63 M. | |
| GeneDx Holdings generates negative cash flow from operations | |
| GeneDx Holdings Corp has a frail financial position based on the latest SEC disclosures | |
| Over 87.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients |
- Analyzing GeneDx Holdings' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GeneDx Holdings' stock is overvalued or undervalued compared to its peers.
- Examining GeneDx Holdings' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GeneDx Holdings' management team can have a significant impact on its success or failure. Reviewing the track record and experience of GeneDx Holdings' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GeneDx Holdings' stock. These opinions can provide insight into GeneDx Holdings' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for GeneDx Stock Analysis
When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.